The EBODAC project (Ebola Vaccine Deployment, Acceptance and Compliance) is developing strategies and tools to promote the acceptance and uptake of new Ebola vaccines, to help the right person receive the right vaccine at the right time.

EBODAC is important because the successful development and deployment of an Ebola vaccine is faced with many challenges, especially when working in resource limited settings.

The project is supporting clinical trials of Ebola vaccines in Sierra Leone, while simultaneously preparing for the future deployment of a licensed vaccine through a series of linked projects focused on communications, community engagement, and enabling technologies.

Supporting Ebola vaccine trials in Sierra Leone

EBODAC communications and engagement strategies and tools are being used to support Ebola vaccine trials, while building capacity in Sierra Leone to use these resources in the future.

All components of the EBODAC platform are designed and developed to allow rapid and efficient scale-up should there be a need to deploy a licensed vaccine.

Preparing for the future deployment of a licensed vaccine

EBODAC is delivering a series of projects to build local knowledge and capacity and strengthen health systems, in preparation for the potential future use of a licensed Ebola vaccine in several potential deployment scenarios.

Sharing expertise

The EBODAC consortium is committed to sharing the expertise and lessons learned from using community engagement, communication and technology while conducting clinical trials related to Ebola in an outbreak setting. In February 2017 EBODAC organised a symposium on this theme in Dakar, Senegal, which brought together experts from across Africa and beyond. The learnings from the symposium have contributed to a training resource which is now available as an open-access tool for anybody who is interested in community engagement, communications and enabling technologies for clinical trials in outbreak settings.

Learn more

Learn more about EBODAC with our short Introduction to EBODAC animation.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Copyright © 2021 Ebovac | Terms and Conditions | WordPress development by Toast.